Parkon® in the treatment of multiple sclerosis. A pilot study
<p>Multiple Sclerosis (MS) is one of the most common chronic demyelinating diseases of the central nervous system. The disease affects and relatively quickly leads to disability in mainly people 15-40 years of age. The development of MS can occur progressively or with exacerbations and remissi...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Book |
| Published: |
Open Journal of Parkinson's Disease and Treatment - Peertechz Publications,
2020-08-07.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|